Commerce Dashboard

Panacea Biotec

Go Back

Panacea Biotec

  • First company to develop fully liquid Pentavalent vaccine (DTwP+Hep B+Hib) Easy Five in 2005.
  • The company registered growth of 44% in September 2019 compared with September 2018.
  • It has state-of-art production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi to manufacture tablets, capsules, ointments liquids, herbal formulations and vaccines.

Panacea Biotec was established in 1984 under the name Panacea Drugs Private Limited and got publicly listed in September 1995. The company does research and development, manufacturing, sales, distribution and marketing of pharmaceuticals, vaccines and biosimilars. The company’s portfolio includes prescription products in niche therapeutic areas such as pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal care products and vaccines.

Source: http://www.panaceabiotec.com/

Panacea Biotec – Innovation in support of life

2020 Panacea Biotec announced successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll
Panacea Biotec and Refana collaborate to develop COVID-19 vaccine
Panacea transfers pharmaceuticals business to its wholly owned subsidiary ‘Panacea Biotec Pharma Limited’
2019 Launched ViLACT to treat uncontrolled Type-2 Diabetes Mellitus patients
IndiaRF announced investment worth US$ 144million in Panacea Biotec
2018 Partnered with Serum Institute of India to expand market access for the world's first fully liquid wP-based hexavalent vaccine, EasySix. It vaccinates children against DTwP, Hib, Hep. B and Polio
Inked tripartite agreement with Natco Pharma Limited and Breckenridge Pharmaceuticals Inc. to manufacture and supply of Azacitidine injection in the US market
2017 Panacea Biotec announced acceptance of its abbreviated new drug application (ANDA) for paclitaxel protein bound particles by the US FDA
Partnered with Technology Development Board (TDB), Govt. of India, regarding financial assistance for development and commercialisation of Dengue Tetravalent Vaccine
2014 Partnered with a leading pharmaceutical company (name undisclosed) to develop and supply an immunosuppressant generic product in the US
2013 Received WHO PQ for EasyFive TT
2012 Partnered with Kremers Urban for 11 High Barrier to Entry Generics and launched Tacrolimus Capsules in the US
2007 Partnered with Punjab University to develop new chemical entities
Signed an agreement with Family Vaccines to supply combination vaccines in the Philippines
Launched seven anti-cancer products, manufactured by a Mumbai-based company and sold under the brand name of Panacea Biotec
2006 Panacea Biotec partnered with Nederlands Vaccine Instituut under which the latter would supply bulk Inactivated Polio Vaccines (IPV), which will be used by the company in the manufacture of finished IPV and several IPV based combination vaccines
Collaborated with national research development corporation for technology transfer of foot and mouth disease vaccine, developed by Indian Veterinary Research Institute
2004 Collaborated with Cambridge Bio-stability, the UK, for thermo stable vaccines
Marketing Joint Venture with Chiron (now Novartis) Vaccines, the UK
2002 Recombinant vaccine production plant was commissioned
2001 Collaborated with a European MNC for R&D
1995 Established State -of the- art drug delivery R&D centre at Lalru
1993 Panacea Biotec Ltd. was formed with the merger of Panacea Drugs (P) Ltd. & Radicura Pharma
1988 Established a plant to produce vaccines at New Delhi, under the name of Radicura Pharma

 

Biotechnology
The biotechnology industry in India comprises >2700 biotech start-ups and is estimated to reach 10,000 by 2024.